SG11202013175SA - Inhibitors of cyclin-dependent kinases - Google Patents
Inhibitors of cyclin-dependent kinasesInfo
- Publication number
- SG11202013175SA SG11202013175SA SG11202013175SA SG11202013175SA SG11202013175SA SG 11202013175S A SG11202013175S A SG 11202013175SA SG 11202013175S A SG11202013175S A SG 11202013175SA SG 11202013175S A SG11202013175S A SG 11202013175SA SG 11202013175S A SG11202013175S A SG 11202013175SA
- Authority
- SG
- Singapore
- Prior art keywords
- cyclin
- inhibitors
- dependent kinases
- kinases
- dependent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691879P | 2018-06-29 | 2018-06-29 | |
| PCT/US2019/039959 WO2020006497A1 (en) | 2018-06-29 | 2019-06-28 | Inhibitors of cyclin-dependent kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202013175SA true SG11202013175SA (en) | 2021-01-28 |
Family
ID=68985220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013175SA SG11202013175SA (en) | 2018-06-29 | 2019-06-28 | Inhibitors of cyclin-dependent kinases |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10894788B2 (zh) |
| EP (1) | EP3813819A4 (zh) |
| JP (1) | JP2021529740A (zh) |
| KR (1) | KR20210040368A (zh) |
| CN (1) | CN112638373A (zh) |
| AR (1) | AR115646A1 (zh) |
| AU (1) | AU2019291935A1 (zh) |
| BR (1) | BR112020026748A2 (zh) |
| CA (1) | CA3104131A1 (zh) |
| IL (1) | IL279791A (zh) |
| MX (1) | MX2020014245A (zh) |
| SG (1) | SG11202013175SA (zh) |
| TW (1) | TW202016094A (zh) |
| WO (1) | WO2020006497A1 (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11447493B2 (en) | 2018-05-02 | 2022-09-20 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| CN112638373A (zh) | 2018-06-29 | 2021-04-09 | 金耐特生物制药公司 | 细胞周期蛋白依赖性激酶抑制剂 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020180959A1 (en) * | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| AU2020315640A1 (en) * | 2019-07-17 | 2022-03-03 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| AR119765A1 (es) | 2019-08-14 | 2022-01-12 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
| MX2022004390A (es) | 2019-10-11 | 2022-08-08 | Incyte Corp | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). |
| CA3166386A1 (en) * | 2019-12-31 | 2021-07-08 | Kinnate Biopharma Inc. | Treatment of cancer with cdk12/13 inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| EP4387965A2 (en) | 2021-08-18 | 2024-06-26 | ChemoCentryx, Inc. | Aryl sulfonyl compounds as ccr6 inhibitors |
| CA3228553A1 (en) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors |
| TW202329937A (zh) * | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2024032561A1 (en) * | 2022-08-08 | 2024-02-15 | Insilico Medicine Ip Limited | Inhibitors of cyclin-dependent kinase (cdk) 12 and/or cdk13 and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW249201B (zh) * | 1992-07-02 | 1995-06-11 | Otsuka Pharma Co Ltd | |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US20070004763A1 (en) | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
| BR112014002675A2 (pt) | 2011-08-04 | 2017-02-21 | Array Biopharma Inc | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" |
| US20140309184A1 (en) | 2011-09-21 | 2014-10-16 | University Of South Alabama | Methods and compositions for the treatment of ovarian cancer |
| AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
| EP3057954A2 (en) * | 2013-10-18 | 2016-08-24 | Syros Pharmaceuticals, Inc. | Heteromaromatic compounds useful for the treatment of proliferative diseases |
| ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2016073420A1 (en) * | 2014-11-05 | 2016-05-12 | Dart Neuroscience, Llc | Substituted azetidinyl compounds as glyt1 inhibitors |
| EP3236959A4 (en) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2978518C (en) * | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
| WO2016193939A1 (en) | 2015-06-04 | 2016-12-08 | Aurigene Discovery Technologies Limited | Substituted heterocyclyl derivatives as cdk inhibitors |
| AU2016276963C1 (en) * | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CA2988330A1 (en) * | 2015-06-26 | 2016-12-29 | Dana-Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| GB201605126D0 (en) | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| AU2017363307B2 (en) * | 2016-11-22 | 2021-07-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof |
| KR20190092476A (ko) * | 2016-12-19 | 2019-08-07 | 이소큐어 바이오사이언스 인코퍼레이티드 | 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법 |
| WO2019035866A1 (en) * | 2017-08-15 | 2019-02-21 | The Brigham & Women's Hospital, Inc. | COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX |
| GB201715342D0 (en) | 2017-09-22 | 2017-11-08 | Univ Nottingham | Compounds |
| US11447493B2 (en) | 2018-05-02 | 2022-09-20 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| CN112638373A (zh) | 2018-06-29 | 2021-04-09 | 金耐特生物制药公司 | 细胞周期蛋白依赖性激酶抑制剂 |
| AU2020315640A1 (en) | 2019-07-17 | 2022-03-03 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| CA3166386A1 (en) | 2019-12-31 | 2021-07-08 | Kinnate Biopharma Inc. | Treatment of cancer with cdk12/13 inhibitors |
-
2019
- 2019-06-28 CN CN201980057125.9A patent/CN112638373A/zh active Pending
- 2019-06-28 EP EP19825341.1A patent/EP3813819A4/en active Pending
- 2019-06-28 CA CA3104131A patent/CA3104131A1/en active Pending
- 2019-06-28 US US16/457,400 patent/US10894788B2/en active Active
- 2019-06-28 MX MX2020014245A patent/MX2020014245A/es unknown
- 2019-06-28 TW TW108122977A patent/TW202016094A/zh unknown
- 2019-06-28 AU AU2019291935A patent/AU2019291935A1/en active Pending
- 2019-06-28 JP JP2020571485A patent/JP2021529740A/ja active Pending
- 2019-06-28 AR ARP190101813A patent/AR115646A1/es unknown
- 2019-06-28 SG SG11202013175SA patent/SG11202013175SA/en unknown
- 2019-06-28 WO PCT/US2019/039959 patent/WO2020006497A1/en active Application Filing
- 2019-06-28 BR BR112020026748-1A patent/BR112020026748A2/pt not_active Application Discontinuation
- 2019-06-28 KR KR1020217002677A patent/KR20210040368A/ko active Search and Examination
-
2020
- 2020-11-11 US US17/095,672 patent/US11390618B2/en active Active
- 2020-12-27 IL IL279791A patent/IL279791A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3104131A1 (en) | 2020-01-02 |
| US20200024266A1 (en) | 2020-01-23 |
| MX2020014245A (es) | 2021-05-12 |
| IL279791A (en) | 2021-03-01 |
| WO2020006497A1 (en) | 2020-01-02 |
| AU2019291935A1 (en) | 2021-02-04 |
| US20210130340A1 (en) | 2021-05-06 |
| EP3813819A1 (en) | 2021-05-05 |
| EP3813819A4 (en) | 2022-08-17 |
| AR115646A1 (es) | 2021-02-10 |
| CN112638373A (zh) | 2021-04-09 |
| BR112020026748A2 (pt) | 2021-03-30 |
| JP2021529740A (ja) | 2021-11-04 |
| TW202016094A (zh) | 2020-05-01 |
| US10894788B2 (en) | 2021-01-19 |
| US11390618B2 (en) | 2022-07-19 |
| KR20210040368A (ko) | 2021-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279791A (en) | Inhibitors of cyclin-dependent kinases | |
| HK1246645A1 (zh) | 細胞周期蛋白依賴性激酶的抑制劑 | |
| IL292422A (en) | Cyclin-dependent kinase 7 (cdk7) inhibitors | |
| IL282737A (en) | Cyclin-dependent kinase 7 (CDK7) inhibitors | |
| HK1245260A1 (zh) | 細胞週期蛋白依賴性激酶7(cdk7)的抑制劑 | |
| EP3347018A4 (en) | HEMMER OF CYCLINE-DEPENDENT KINASES | |
| IL247915A0 (en) | Cyclin-dependent kinase 7 (cdk7) inhibitors | |
| IL267215A (en) | Imidazopyrrolopyridines as inhibitors of the jak family of kinases | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| IL271930A (en) | Heterocyclic inhibitors of ATR kinase | |
| LT3700902T (lt) | Trpc6 inhibitoriai | |
| IL271109A (en) | Imidazole-containing alk2 kinase inhibitors | |
| EP3902805A4 (en) | CYCLIN DEPENDENT KINASE INHIBITORS | |
| PT3613737T (pt) | Novo inibidor de cinase cdk9 dependente de ciclina | |
| EP3787629A4 (en) | INHIBITORS OF CYCLINE-DEPENDENT KINASES | |
| EP3999498A4 (en) | CYCLIN-DEPENDENT KINASE INHIBITORS | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| EP3902801A4 (en) | CYCLINE-DEPENDENT KINASE INHIBITORS | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL277866B1 (en) | Aminothiazoles were substituted as nuclease inhibitors | |
| EP3752518A4 (en) | CYCLINE DEPENDENT KINASE INHIBITORS AND METHOD OF USING | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201614783D0 (en) | Kinases inhibitors |